Canaccord Genuity Maintains Buy on Guardant Health, Lowers Price Target to $30
Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:GH) with a Buy and lowers the price target from $45 to $30.
Guardant Health Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/29/2024 66.67% Canaccord Genuity $45 → $30 Maintains Buy 04/24/2024 55.56% Craig-Hallum → $28 Assumes →
Laboratory Corporation of America on Pace for Largest Percent Increase Since November 2022 -- Data Talk
Laboratory Corporation of America Holdings (LH) is currently at $206.91, up $8.51 or 4.29% --On pace for largest percent increase since Nov. 10, 2022, when it rose 5.44% --Currently up two consecuti
Express News | Labcorp Shares Are Trading Higher After the Company Announced That the FDA Approved Its NABCyte Anti-AAVRh74var HB-FE Assay, a Companion Diagnostic, to Determine Patient Eligibility for Treatment With BEQVEZ
Research Alert: CFRA Maintains Hold Opinion On Shares Of Revvity, Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lower our target price to $103 from
MRNA Is Promising A Breakthrough In Fighting Cancer
When it comes to cancer, there's innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all got acquainted with during the COVID-19 era as i
am00se : how to know our tp master
potsy52 am00se: Don’t ask tp/ he’ll let you know when good time to sell